Taro Pharma (TARO) Misses Q4 EPS by 68c
Get Alerts TARO Hot Sheet
Join SI Premium – FREE
Taro Pharma (NYSE: TARO) reported Q4 EPS of $0.19, $0.68 worse than the analyst estimate of $0.87. Revenue for the quarter came in at $139.2 million versus the consensus estimate of $163.12 million.
For earnings history and earnings-related data on Taro Pharma (TARO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- First Industrial Realty (FR) Tops Q1 EPS by 21c
- William Penn Bancorporation (WMPN) Tops Q3 EPS by 1c
- Crown Castle (CCI) Tops Q1 EPS by 1c; maintains outlook for FY24
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!